Is There a Tirzepatide Pill? What Actually Exists in 2026

No. As of October 2026, there is no FDA-approved tirzepatide pill, tablet, drop or under-the-tongue form. Tirzepatide is approved only as a once-weekly injection under the skin. If you want a GLP-1 medicine you can swallow, the FDA-approved options are different drugs: oral semaglutide tablets and orforglipron, a newer once-daily pill.

• Tirzepatide is FDA-approved only as a weekly injection, starting at 2.5 mg and going up to 15 mg.
• Tirzepatide is a large peptide, and peptides are mostly broken down or blocked in the gut.
• Oral and under-the-tongue tirzepatide sold online is not FDA-approved, and there is no published human evidence that it absorbs well.
• FDA-approved GLP-1 pills do exist, but they contain semaglutide or orforglipron, not tirzepatide.
• In trials, weekly tirzepatide injections produced more average weight loss than the approved pills did in their own trials.

The short answer: tirzepatide is injection-only

Tirzepatide is a medicine that acts on two gut hormone receptors, GIP and GLP-1. It lowers appetite and helps the body handle blood sugar. If you are new to it, our guide on what tirzepatide is and how it works covers the basics.

Every FDA-approved form of tirzepatide is an injection. The prescribing information describes a once-weekly shot under the skin of the belly, thigh or upper arm. The starting dose is 2.5 mg once a week for 4 weeks. The dose can go up in 2.5 mg steps, no faster than every 4 weeks, to a top dose of 15 mg once a week (Lilly prescribing information).

So when you search "tirzepatide pills," you will mostly find two things: news about other GLP-1 pills, and online sellers offering tirzepatide tablets, drops or dissolving strips that the FDA has never approved. We cover both below.

Why tirzepatide is hard to give by mouth

Tirzepatide is a peptide, a chain of amino acids, and a big one. Its molecular weight is about 4,814 daltons (Lilly prescribing information). Most pills you take every day are much smaller molecules, often under 500 daltons.

Large peptides run into three problems when you swallow them:

• Stomach acid and enzymes break them down. Your gut is built to digest proteins and peptides into pieces, which is exactly what you do not want to happen to a medicine.
• They are too big to pass through the gut wall easily. The lining of the intestine and the mouth lets small molecules through far more easily than large ones.
• They do not dissolve into cell membranes well. Peptides attract water, so they do not slip through the fatty layers of cells on their own.

A 2025 review of oral peptide delivery estimated that only about 1% to 2% of a peptide dose reaches the bloodstream when swallowed the usual way, and about the same when placed in the cheek or under the tongue (Biomedicines, 2025). By contrast, about 80% of a tirzepatide dose reaches the blood after an injection under the skin (Lilly prescribing information).

Getting a peptide pill to work took years of formulation research and large clinical trials to show the right amount reached the blood. No one has published that kind of human data for an oral tirzepatide product.

What "tirzepatide pills" and drops sold online really are

Some websites sell tirzepatide as tablets, capsules, drops, sprays or strips that dissolve under the tongue. These products are made by compounding pharmacies or other sellers. Here is what you should know before buying one:

• They are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness or quality before they are sold (FDA).
• There is little evidence they absorb. We could not find any published human study showing how much oral or under-the-tongue tirzepatide reaches the blood. Given what is known about large peptides, the amount is likely very small.
• The dose you get is uncertain. If very little is absorbed, and absorption varies from person to person, the label strength on the bottle tells you little about what your body actually receives.
• Side effect reports may be missing. The FDA says adverse events from compounded versions of these drugs are likely underreported (FDA).

The FDA has also sent warning letters to companies selling unapproved tirzepatide, including products falsely labeled "for research purposes" or "not for human consumption." It urges people to buy only from state-licensed pharmacies (FDA).

Is compounded tirzepatide still allowed?

The FDA declared the tirzepatide injection shortage resolved on December 19, 2024. Pharmacies can no longer rely on the shortage to make copies in bulk. A state-licensed 503A pharmacy may still compound tirzepatide for an individual patient with a prescription, including when the prescriber documents a clinical need for a change, such as a different dose or formulation (FDA). Compounded tirzepatide is not FDA-approved and is not the same as any brand-name medication.

Being allowed to compound a product does not mean a pill or drop form works. Compounded tirzepatide injections at least use the same route (under the skin) that tirzepatide was studied with. Oral and under-the-tongue versions have no published human absorption data behind them. For a deeper look at quality and safety questions, see our guide to compounded tirzepatide.

The GLP-1 pills the FDA has approved

If a pill is what you want, these are the FDA-approved oral GLP-1 medicines as of October 2026. None of them contain tirzepatide.

Rybelsus and Ozempic tablets (oral semaglutide for type 2 diabetes)

The FDA approved Rybelsus in September 2019 as the first GLP-1 medicine in the U.S. that does not need to be injected (FDA). The current label also covers a newer tablet sold as Ozempic tablets. Both are taken once daily and are approved to improve blood sugar in adults with type 2 diabetes and to lower the risk of major heart events in adults with type 2 diabetes at high risk. They are not approved for weight loss. Rybelsus comes in 3 mg, 7 mg and 14 mg; Ozempic tablets come in 1.5 mg, 4 mg and 9 mg, and the two are not swapped mg for mg (FDA label).

Wegovy pill (oral semaglutide for weight management)

Novo Nordisk announced FDA approval of the Wegovy pill on December 22, 2025, as the first oral GLP-1 for obesity in the U.S. (Novo Nordisk). It is approved, along with diet and exercise, to reduce excess weight and keep it off in adults with obesity, or with overweight and at least one weight-related condition, and to lower the risk of major heart events in adults with heart disease and obesity or overweight.

It is taken once daily. The dose starts at 1.5 mg and steps up every 30 days to 4 mg, then 9 mg, reaching the 25 mg maintenance dose from day 91. You take it in the morning on an empty stomach with up to 4 ounces of plain water, then wait at least 30 minutes before eating, drinking or taking other pills (FDA label).

In the 64-week OASIS 4 trial, people on the 25 mg pill lost about 13.6% of their body weight on average, versus 2.4% on placebo, counting everyone who started. Among people who stayed on treatment, the average was 16.6% (Novo Nordisk).

Foundayo (orforglipron for weight management)

The FDA approved Lilly's Foundayo (orforglipron) on April 1, 2026, for adults with obesity, or with overweight and at least one weight-related condition, along with diet and exercise (Lilly). Lilly describes orforglipron as a small-molecule, non-peptide GLP-1 drug. Because it is not a peptide, it does not need an absorption helper, and the label says to take it once daily with or without food (Foundayo prescribing information).

It comes in six strengths from 0.8 mg to 17.2 mg, starting at 0.8 mg and stepping up no faster than every 30 days. In the 72-week Trial 1 on the label, people without diabetes on the 17.2 mg dose lost 11.1% of their body weight on average, versus 2.1% on placebo (Foundayo prescribing information).

Approved pills vs the tirzepatide injection

This table compares the FDA-approved oral GLP-1 options with FDA-approved tirzepatide. Weight loss figures come from each drug's own trial and are not head-to-head results, so treat them as a rough guide only.

Sources: Zepbound label, Novo Nordisk OASIS 4 results, Foundayo label, Rybelsus label. To compare the two main injectable molecules, see semaglutide vs tirzepatide.

Who might prefer a pill

A weekly shot works well for many people, and most find the small needle easier than they expected. Still, a daily pill can make sense for some:

• Strong fear of needles. If you would skip doses rather than inject, a pill you will actually take may serve you better.
• Travel and storage. Pills do not need the cold storage and sharps disposal that injections do.
• A moderate weight loss goal. In their own trials, the approved pills produced less average weight loss than tirzepatide at its top dose. For some people, that is enough.
• Keeping weight off after losing it. Some people and their providers consider a pill for the maintenance stage. Ask your provider whether that fits your situation.

A pill may be a weaker fit if you want the largest average weight loss, find a daily routine harder than a weekly one, or take morning medicines that would clash with the empty-stomach rule for oral semaglutide.

Finding the lowest-cost path

Before paying cash, check what your insurance covers. Coverage for weight-loss medicines varies a lot by plan, and a covered brand-name medicine with a savings card can cost far less than paying out of pocket.

If you pay yourself, the drug makers sell direct. Novo Nordisk lists Wegovy pill self-pay prices of $149 a month for 1.5 mg, $199 for 4 mg and $299 for 9 mg and 25 mg (NovoCare). LillyDirect lists Foundayo self-pay prices starting at $149 a month for the lowest doses and rising to $299 at the higher doses, with some prices temporarily reduced through December 31, 2026 (LillyDirect). Prices and offer terms can change, so check the official pages before you decide.

For brand-name tirzepatide pricing, see our breakdown of Zepbound cost by dose.

Getting treatment through Rx.com

Rx.com does not offer a tirzepatide pill, because no approved one exists and we do not sell oral or under-the-tongue tirzepatide. If you and a provider decide tirzepatide is right for you, Rx.com offers compounded tirzepatide injections from $149/month on a 12-month plan. That price includes an online provider visit, medication, supplies and cold shipping, at one flat price at every dose, with no insurance needed. A licensed provider reviews your health history to decide whether it is appropriate for you.

Compounded tirzepatide is not FDA-approved and is not the same as any brand-name medication. To check whether you might qualify, start with our weight loss quiz, or read about what compounded tirzepatide costs each month and how tirzepatide doses step up.

Sources

1. Eli Lilly and Company. Zepbound (tirzepatide) prescribing information. uspl.lilly.com
2. Eli Lilly and Company. Foundayo (orforglipron) prescribing information. uspl.lilly.com
3. Eli Lilly and Company. FDA approves Lilly's Foundayo (orforglipron). April 1, 2026. investor.lilly.com
4. Eli Lilly and Company. LillyDirect: Foundayo self-pay pricing. lilly.com
5. U.S. Food and Drug Administration. Rybelsus and Ozempic (semaglutide) tablets prescribing information, revised January 2026. accessdata.fda.gov
6. U.S. Food and Drug Administration. Wegovy (semaglutide) injection and tablets prescribing information. accessdata.fda.gov
7. Novo Nordisk. FDA approves oral Wegovy pill. December 22, 2025. novonordisk-us.com
8. Novo Nordisk. NovoCare self-pay pricing for Wegovy. novocare.com
9. U.S. Food and Drug Administration. FDA approves first oral GLP-1 treatment for type 2 diabetes. September 20, 2019. fda.gov
10. U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss. fda.gov
11. U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. fda.gov
12. Amer AA, Bingle L, Elkordy AA, Chaw CS. Overcoming oral cavity barriers for peptide delivery using advanced pharmaceutical techniques and nano-formulation platforms. Biomedicines. 2025;13(11):2735. PMC